Obesity is an increasing health challenge at the global level, and the Scandinavian countries are no exception. About 15–25% of the adult population can be classified as obese (BMI > 30 kg/m²), and the majority of the population is overweight (BMI > 25 kg/m²), which causes numerous comorbidities, disability, and reduced life expectancy. While prevention of weight gain, overweight and obesity is preferred, there are only early indications of a leveling off of the increase in prevalence, and a large part of the obese population is seeking treatment. Many obese individuals manage to lose weight by following various diet and exercise programs, commercial weight loss plans, and using meal replacements, but there is an increasing demand for adjunct therapy that can enhance initial weight loss efforts and improve long term weight loss maintenance. Bariatric surgery is an option for morbidly obese patients, but the majority of obese subjects do not fulfill the criteria for such surgical interventions. For some patients this gap may be bridged with dietary supplements, medical devices, and pharmacological compounds. The purpose of this review is to provide an update on the management options available in Scandinavia, and present a brief assessment of efficacy and safety, and clinical directions for choices for the individual patient.

When previously approved pharmaceutical agents such as sibutramine and rimonabant were withdrawn from the market due to potential serious adverse effects, only orlistat and amfepramone were left. However, in 2015 two new compounds were approved in the EU for weight reduction: liraglutide 3 mg (Saxenda®), and naltrexone/bupropion (Mysimba®). We therefore present a brief updated summary of the use of orlistat and amfepramone, and a section on the two novel compounds. Furthermore for patients with S, the GLP-1 analogues and SGLT2 inhibitors are available.
providing both glucose control and weight loss. Moreover, a number of dietary supplements and medical devices have been approved for weight control, and these products are also reviewed. We have included products available in at least two Scandinavian countries.

1. Pharmaceutical compounds

1.1. Orlistat (Xenical®, Alli®)

Orlistat has withstood the test of time, remaining the only approved therapy in Europe since 1998 for long-term treatment of obesity. Orlistat potently and selectively inhibits gastric and intestinal lipase, reducing intestinal fat absorption. While orlistat's inhibition of intestinal fat absorption is minimal when dietary fat intake is very low, the proportion of fat excretion increases in a dose-dependent manner with increasing dietary fat, reaching a plateau of about 30% with the usual dose of 120 mg three times daily (Hauptman et al., 1992). In addition, orlistat may increase glucagon-like peptide 1 secretion (Damci et al., 2004).

1.1.1. Weight loss efficacy

In a meta-analysis of 16 randomized, placebo-controlled trials of ≥1 year orlistat reduced body weight by 2.9 kg (95% confidence interval [CI] 2.5–3.2 kg) compared with placebo (Rucker et al., 2007). In a recent systematic review of studies with at least 50 participants per group and at least 50% retention, an intention-to-treat analysis found that orlistat gave a 3.4 kg greater weight loss (3.1% of initial weight) than placebo (Yanovski and Yanovski, 2014). Two trials of orlistat 60 mg three times daily found a 2.5 kg greater weight loss than with placebo at 12 months (Yanovski and Yanovski, 2014). In patients with T2D, the difference between orlistat and placebo was about 2 kg (Norris et al., 2005; Jacob et al., 2009).

1.1.2. Weight maintenance

In a trial in 3304 participants most of the weight loss difference at 1 year (11.4 kg for orlistat versus 7.5 kg for placebo) was preserved in those that completed all four years of the study (6.9 kg for orlistat versus 4.1 kg for placebo) (Torgerson et al., 2004). Other trials have looked specifically at orlistat as a weight maintenance treatment following weight loss induced by orlistat, conventional dieting or a very low energy diet (VLED). In one trial orlistat administered for three years after VLED significantly reduced weight regain compared to placebo (4.6 kg versus 7.0 kg) (Richelsen et al., 2007). A meta-analysis found that orlistat effectively maintained weight loss at 12 months, with a difference of 1.8 kg (95% CI 1.06 to 2.54) compared to placebo (Dombrowski et al., 2014).

1.1.3. Glycemic control in T2D

In a retrospective analysis involving 2550 overweight or obese patients with T2D, participants treated with orlistat for 6–12 months had significantly larger decreases in HbA1c compared to placebo (−0.74% vs. −0.31%) (Jacob et al., 2009).

1.1.4. Prevention of T2D

In a 4-year randomized, controlled trial, orlistat added to lifestyle changes resulted in a 37.3% reduction in the incidence of T2D (Torgerson et al., 2004). Pooled data from three studies has indicated that orlistat prevented progression to diabetic status in subjects with impaired glucose tolerance (Heysmfield et al., 2000).

1.1.5. Cardiovascular risk factors

Orlistat improves most cardiovascular risk factors. Reductions in visceral fat (Tilkkainen et al., 2004), LDL cholesterol (Muls et al., 2001) and glycemia (Jacob et al., 2009), and improved insulin sensitivity (Kelley et al., 2004), appear in part to be independent of weight loss. In patients with hypertension, orlistat improved systolic blood pressure by −2.5 mm Hg (95% CI, 4.0 to −0.9 mmHg) and diastolic blood pressure by −1.9 mm Hg (95% CI −3.0−0.9 mmHg) (Siebenhofer et al., 2013). A recent meta-analysis found that orlistat increased adiponectin and reduced leptin and C-reactive protein (Derosa et al., 2015).

1.1.6. Safety and tolerability

Gastrointestinal effects including oily spotting, flatus with discharge, fecal urgency and steatorrhea are common, though they tend to subside as patients learn to adjust fat intake. The risk ratio for discontinuation of orlistat compared to placebo due to adverse events in randomized controlled trials was 1.59 (95% CI, 1.21–2.08), with a number needed to harm of 39 (95% CI, 25–83) (Johansson et al., 2009). Rare cases of liver injury have been reported. However, the UK Clinical Practice Research Datalink found no evidence of an increased risk of liver injury (Douglas et al., 2013). Orlistat interferes with the absorption of several drugs and fat-soluble vitamins (Filippatos et al., 2008) and may cause acute kidney injury (Kwan et al., 2013).

1.1.7. Clinical use

Orlistat is indicated for the treatment of obesity (BMI ≥30 kg/m²) or overweight (BMI 27–29.9 kg/m²) with associated risk factors, in conjunction with a modestly fat-reduced diet. Attrition rates are high, mostly due to high cost and side effects (Padwal et al., 2007), as well as difficulty in complying with dietary recommendations (Svendsen et al., 2009) and the popularity of low carbohydrate diets. A study suggested that a low-carbohydrate ketogenic diet leads to similar weight loss as orlistat combined with a low fat diet (Yancy et al., 2010). Beneficial long-term effects of orlistat on cardiovascular disease parameters have not been demonstrated.

1.2. Amfepramone

Amfepramone (diethylpropion) is approved in the EU for treatment of obesity for short durations (4–6 weeks and no longer than 3 months) under various brand names (Anorex®, Dobesin®, Regenon® etc.). The drug is closely related to amphetamines and possesses some of the same CNS stimulant properties and abuse potential, and has been associated with serious cases of primary pulmonary hypertension. In 1999 the Committee for Proprietary Medicinal Products (CPMP) recommended a stop to the use of amfepramone for obesity treatment and a stop to the sale of this drug in EU countries. In the Scandinavian countries it is available only in Denmark, but its use cannot be recommended.

1.3. Liraglutide 3 mg (Saxenda®)

GLP-1 is an endogenous hormone released from L-cells in the small intestine in response to the presence of food (peptides and monoglycyrates), and it acts both as an incretin that stimulates the postprandial release of insulin, and as a satiety hormone. It is cleared from the bloodstream within minutes, but injectable analogues have been developed that can be given once daily, or even only once weekly, and a number of such agents have been approved for the management of T2D (e.g. exenatide, liraglutide). GLP-1 agonists in dosages used for treatment of T2D have been found to produce a small weight loss (Wang et al., 2014). Liraglutide is used in the doses 1.2 and 1.8 mg daily for T2D (Victoza®), but higher dosages are required for a clinically relevant weight loss in obese patients (i.e. 3 mg).
1.3.1. Weight loss efficacy. A large phase III program (SCALE) using liraglutide 3 mg daily was based on a phase II program that demonstrated that the dose of 3 mg was effective for weight control over one year in obese patients (Astrup et al., 2009; Scheen, 2015). Liraglutide 3 mg produced a mean weight loss of 8 kg as compared to 2 kg in the placebo group, and 4 kg in the orlistat reference group (Scheen, 2015) (Fig. 1). After two years follow-up the weight loss was 5.3 kg with liraglutide and 2.3 kg with orlistat (Fig. 1) (Astrup et al., 2012). The group which received placebo for the first year and subsequently switched to liraglutide achieved a weight loss that was indistinguishable from the group which had received liraglutide 3 mg from the start. After two years 52% of the patients on liraglutide 3 mg had maintained more than 5% weight loss, and 26% more than 10%. The prevalence of prediabetes and metabolic syndrome was reduced, and so were blood pressure and lipids following liraglutide as compared with placebo (Fig. 2).

1.3.2. Safety and tolerability. The effects of liraglutide are well known from the use of lower dosages for T2D. Side effects are mainly gastrointestinal with nausea, vomiting, obstipation, and diarrhea, which are mild and transient in nature in most cases (Shyangdan et al., 2010). The adverse effects can be reduced by a slow up-titration of the dosage. Independent of dosage liraglutide increases heart rate by 2–4 bpm, but meta-analyses have found that liraglutide is associated with reduced incidence of cardiovascular events (Monami et al., 2014). A slightly increased risk of pancreatitis has been reported with the use of liraglutide and other GLP-1 agonists. For liraglutide 3 mg the incidence was 0.4 cases per 100 patient-years treatment as compared to ca. 0.1% with placebo (Pi-Sunyer et al., 2015).

1.3.3. Clinical use. Victoza® which is the trade name for liraglutide in doses of 1.2 or 1.8 mg per day is indicated for the treatment of T2D and not indicated for the treatment of overweight or obesity. Saxenda®, on the other hand, is the trade name for liraglutide in the dose of 3 mg per day for the treatment of obesity or overweight (BMI ≥27 kg/m²) with weight-related comorbidities. The weight loss that occurs on diet and liraglutide during the first 3–12 weeks is a good predictor of the individual long term outcome, and if the patient fails to lose at least 5% of initial body weight after 3 months the treatment should be discontinued.

The manufacturer of liraglutide recommends that Saxenda® be used especially for subjects with BMI ≥35 kg/m² and weight-related comorbidities such as hypertension, dyslipidemia or obstructive sleep apnea. The argument is that this group of patients suffers the most from their obesity and therefore these patients are in particular need of treatment. Generally, health authorities in many countries have acknowledged the imminent need for treatment of people with ≥35 kg/m², as exemplified by reimbursement of bariatric surgery for this particular group of patients. However, reimbursement of liraglutide through public monies is not yet available in Scandinavia.

2. Pharmaceutical combinations in obesity treatment

Several reasonably effective anti-obesity drugs have been withdrawn from the market because of unacceptable side effects. At the same time no novel, effective anti-obesity drug can be foreseen. It is therefore understandable that the pharmaceutical industry has been looking for ways to recycle old and well-established drugs, which are already approved for other clinical indications. This saves time and toxicology work to establish safety, and hence is cost-effective. Two such products have recently been developed. Qsiva® is a combination of topiramate and phentermine, but in considerably lower doses than when used for their initial indications. The observation of weight loss in patients treated with topiramate for epilepsy led to attempts to develop topiramate into an anti-obesity drug. This was not successful at the usual dosage levels used because of side effects (Astrup et al., 2004), which then led to attempts to combine low dose topiramate with another compound instead. Phentermine has been widely used for short-term treatment of obesity for decades. In a low dose combination the compounds were found to potentiate their effects on weight loss, and the product was eventually released as Qnexa®, later Qsiva® in the US and some other countries (Jordan et al., 2014). However, European regulating authorities determined that the potential side effects were not documented well enough and the drug has not been approved in EU. Therefore it will not be further discussed here. However, the other drug combination, which indeed has been approved in the EU, will be presented below.

2.1. Naltrexone/bupropion (Mysimba®)

Mysimba® is a combination of two compounds (Naltrexone 7.2 mg/bupropion 78 mg), each of which has been previously approved for clinical indications other than weight loss. Both compounds appear as extended release forms (ER). Naltrexone is an opioid receptor antagonist blocking all three opioid receptors. The compound is currently used in the treatment of alcohol dependence. For this indication the dosage is 50 mg daily. Bupropion is an

![Weight loss for different treatment interventions](image)

Fig. 1. The average effect of treatment of obesity by lifestyle intervention alone and in combination with pharmaceutical compounds, and the effect of various forms of bariatric surgery.
antidepressant which has been used for several indications in addition to the mood effect, such as smoking cessation and as an adjunct in treatment of attention deficit hyperactivity disorder. Bupropion is an uptake inhibitor of dopamine and noradrenaline in the central nervous system. The drug also acts as a nicotine antagonist on the acetylcholine receptor causing nicotine dependence. The dosage for these indications ranges around 150—300 mg daily.

The combination of the two compounds has a synergistic effect in the treatment of obesity and leads to weight reduction, although the dose of each compound is far lower than the dosages for the initial indications. When given together their action reduces appetite, and possibly also increases energy expenditure, leading to a negative energy balance and ensuing weight loss (Yanovski and Yanovski, 2015). With weight loss the anticipated effects of improvement of obesity-associated risk factors have been observed. In 2015 the EU approved Mysimba® for use in the entire EU region. In summarizing the characteristics of the drug the committee concluded that although the weight loss effects were modest, they were still clinically significant.

2.1.1. Clinical use

Mysimba® is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for weight loss treatment in adult patients (≥18 years) with a BMI of ≥30 kg/m² (obese), or ≥27 kg/m² to < 30 kg/m² (overweight) in the presence of one or more weight-related co-morbidities (e.g.T2D, dyslipidemia, or controlled hypertension). Mysimba® is administered in gradually increasing doses from one tablet daily with a meal to the maximum dose of two tablets twice daily. Treatment with Mysimba® should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight.

2.1.2. Adverse effects

There was a certain concern about the possible side effects of the drug (cardio-vascular complications and a slightly increased risk of epileptic fits) but the committee concluded that these could be managed simply by drug withdrawal. In clinical practice modest nausea seems to be the main side effect.

2.2. Sodium-glucose co-transporter type 2 (SGLT2) inhibitors

Weight loss is of prime importance for patients with T2D, of whom the majority are either overweight or obese. The choice of antidiabetic medication should aim at weight neutrality or reduction, such as GLP-1 receptor agonists and sodium-glucose co-transporter type 2 inhibitors. SGLT2 inhibitors (dapagliflozin, canagliflozin and empagliflozin, currently available in Scandinavia), are novel antidiabetic agents that induce a small weight loss. They increase glucose excretion into the urine and reduce hyperglycemia by inhibiting renal SGLT2 that is responsible for the reabsorption of most of the glucose (Scheen, 2015). The currently available SGLT2-inhibitors have similar pharmacologic characteristics.

2.2.1. Clinical efficacy and use

It is well documented that SGLT2-inhibitors reduce HbA1c by 0.7—1.0% from a mean of 7.5—9.0% in T2D patients treated with diet and exercise, or with any glucose-lowering agents (Scheen, 2015). Due to the increased caloric loss associated with reduced renal reabsorption of glucose, SGLT2-inhibitors induce weight loss in overweight and obese patients with T2D (Barnett, 2013). An early weight loss of 1—2 kg is usually seen as a result of osmotic and diuretic fluid loss upon the initiation of therapy by any SGLT2-inhibitor. However, reduction of body weight by weeks 24 and thereafter, amounting to an average of about 2—4 kg, now well-documented up to four years, has been shown to be predominantly due to loss of fat mass.

2.2.2. Safety and tolerability

In studies with SGLT2-inhibitors a slight reduction of systolic and diastolic blood pressure has been documented. The effect of empagliflozin on cardiovascular morbidity and mortality has recently been reported in a study of 7020 patients with T2D, followed for an average of three years. As compared to placebo, empagliflozin resulted in a significantly lower risk of cardiovascular and total death (HR 0.62, 95% CI: 0.49 to 0.77, and 0.68, 95% CI 0.57 to 0.82), as well as hospitalization for heart failure (HR 0.65, 95% CI: 0.50 to 0.85) (Zinman et al., 2015).

SGLT2-inhibitors are usually well tolerated. They slightly increase the risk of urinary tract and genital infections, which however are usually mild and clinically manageable (Scheen, 2015).
3. Dietary supplements

3.1. Glucomannan (Alléovo®, Kilo Trim®, XLS Medical Appetite Reducer® etc.)

Glucomannan or konjac mannan is dietary fiber that has been found to enhance satiety and produce weight loss, and it is approved by EFSA for weight loss in EU (EFSA, 2010). Glucomannan is a soluble-type of fiber that forms a viscous, gel-like mass in the stomach when hydrated, and this gel seems to delay gastric emptying and induce satiety, leading to a decrease in subsequent food intake (EFSA, 2010). EFSA concluded that in order to obtain a weight loss of at least 3 g of glucomannan should be consumed daily in three doses of at least 1 g each, together with 1–2 glasses of water before meals, together with an energy-restricted diet (EFSA, 2010). The target population is overweight adults. The products we assessed on the market did not declare the content of glucomannan, and we found it questionable that they provide the required 3 g per day.

The evidence to substantiate the weight loss claim seems weak. There are no studies lasting more than 3 months. A meta-analysis from 2008 found a significant weight loss by glucomannan of 0.79 kg greater than placebo (Sood et al., 2008). However, more recent and updated meta-analyses of the randomized trials did not find that glucomannan added any weight loss to a diet (Zalewski et al., 2015a, 2015b) (Table 1).

4. Medical devices

4.1. Cactus fig extract (Litramine®, XLS Medical Fat Binder®)

Litramine® is patented fiber complex made from dry leaves of the fig cactus opuntia ficus-indica. The leaves from this cactus are rich in fiber which can bind to fat in the upper part of the

Table 1

<table>
<thead>
<tr>
<th>Compound</th>
<th>Mechanism of action</th>
<th>Effects on weight above placebo</th>
<th>Adverse effects</th>
<th>Status</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dietary supplements</td>
<td>Glucomannan (Alléovo®, Konjak tabletter®, XLS Medical Appetite Reducer® etc.)</td>
<td>Gel-forming fiber</td>
<td>0–0.8 kg over 3 months</td>
<td>Loose stools and diarrhea. Tablets may cause GI blockage due to swelling</td>
<td>Approved by EFSA (EU) for weight loss claim providing an intake of 3 g/day</td>
</tr>
<tr>
<td>Medical devices</td>
<td>Cactus fig fiber (Opuntia ficus-indica) (Litramine®, XLS Medical Fat Binder®)</td>
<td>Fat binder plus appetite suppressant (dietary fiber and plant extracts from Opuntia ficus-indica)</td>
<td>2–3% over 3–6 months</td>
<td>Well tolerated</td>
<td>Approved medical device</td>
</tr>
<tr>
<td></td>
<td>White bean (Phaseolus vulgaris) extract. (XLS Medical Carb Blocker®)</td>
<td>Alpha-amylase inhibitor</td>
<td>2% over 6 months</td>
<td>Gastrointestinal symptoms (bloating and constipation)</td>
<td>Approved medical device</td>
</tr>
<tr>
<td>Pharmaceutical compounds</td>
<td>Orlistat (Allī®, Xenical®)</td>
<td>Lipase-inhibitor</td>
<td>1–2% for low-dose 60 mg (Allī®), and 3% for high-dose 120 mg (Xenical®)</td>
<td>Gastrointestinal symptoms (diarrhea, oily leakage if non-compliant)</td>
<td>Approved in EU: high dose on prescription, low dose OTC</td>
</tr>
<tr>
<td></td>
<td>Liraglutide 3 mg (Saxenda®)</td>
<td>GLP-agonist — enhances satiety and reduces energy intake</td>
<td>5–7% over 3–12 months</td>
<td>GI symptoms (nausea, vomiting). Dose-related side effects</td>
<td>Approved on prescription in USA and EU</td>
</tr>
<tr>
<td></td>
<td>Topiramate/Phentermine (Qsiva®)</td>
<td>Reduced energy intake by suppression of appetite</td>
<td>7–8% over 1–2 years.</td>
<td>Phentermine: cardiovascular stimulation, Topiramate: CNS-related side effects</td>
<td>Approved on prescription in the US, not EU</td>
</tr>
<tr>
<td></td>
<td>Naltrexone/bupropion (Mysimb®)</td>
<td>Reduced energy intake by suppression of appetite</td>
<td>3–5% over 3–6 months</td>
<td>GI symptoms, dry mouth</td>
<td>Approved on prescription in US and EU</td>
</tr>
<tr>
<td></td>
<td>SGLT-2 Inhibitors (Dapagliflozin, Canagliflozin, Empagliflozin)</td>
<td>Increased excretion of glucose in urine</td>
<td>2–4% over 3–6 months, maintained for up to 4 years</td>
<td>Urinary tract and genital infections</td>
<td>Approved for T2D, not for non-diabetic obesity.</td>
</tr>
</tbody>
</table>

*a For the pharmaceutical compounds the weight loss efficacy results are based on large-scale studies, whereas the studies for dietary supplements and medical devices generally are small and of short-term duration.

*b XLS Medical Appetite Reducer is licensed as a medical device
gastrointestinal tract. In the stomach it seems that this complex is enclosed in a gel covering, which can no longer be absorbed and hence is eliminated undigested while trapping some fat, helping in achieving a negative energy balance. Some studies suggest that Litramine® also has a satiety effect since the gel results in a more firm structure of the intestinal content, causing a delay in stomach emptying and therefore possibly a longer feeling of satiety. Litramine® is not absorbed in the body and in the reported clinical studies tolerability has been rated as very good with few exceptions. In a recent review the efficacy and safety of Litramine® has been summarized by the research group from which most of the published work on this compound stems (Chong et al., 2014).

In a study by Uebelhack et al. (2014) the dietary fat binding capacity of Litramine® fiber was determined through analysis of fecal fat excretion in healthy volunteers. Twenty-four-hour feces samples were collected during both the baseline and treatment periods for analysis of the fat content. Subjects given cactus fiber showed a significantly increased fecal fat excretion compared with placebo (16% vs 5%, P < 0.001). In a three-month study 123 obese overweight subjects were treated with Litramine® or placebo (Grube et al., 2013).

The study comprised a two-week run-in phase and an initial 12-week double-blind, placebo-controlled trial phase. The initial BMI-value of the group was 29.6 kg/m² and the middle age 45 years. The mean body weight change from baseline was 3.8 ± 1.8 kg in the Litramine® group vs. 1.4 ± 2.6 kg in the controls (p < 0.001), and 76% of subjects on Litramine® versus 28% on placebo lost at least 3% of the body weight (p < 0.001). Another double-blind, randomized, placebo-controlled study in overweight and obese subjects lasting 24 weeks demonstrated that after 24 weeks the number of responders was higher in Litramine®, treated subjects than in placebo individuals. At the end of the study the difference in weight between the groups was 2.2 kg; 92% in the Litramine® group vs. 25% in controls managed to maintain the weight loss (Grube et al., 2015).

The Litramine® dose is 2 tablets three times daily, which means drug intake with every meal, since the compound is intended to interfere with fat absorption and satiety feelings in connection with ordinary food intake.

4.2. White bean extract — Phaseolus vulgaris (XLS Medical Carb Blocker®)


Richelsen, B., Tonstad, S., 2009. The long-term in...